It is our privilege to welcome you to the Challenges in Cardiology: Cardiology Congress 2018 will take place in the gorgeous city of Rome, Italy in August 16-18, 2018 and the theme of the conference is “Cardiology at the Extremes". The Congress has been designed to provide an innovative and comprehensive overview of the latest research developments in cardiovascular medicine, primarily in the areas of molecular biology, coronary artery disease, heart failure, cardiac arrhythmias and cardiac surgery.
Scientific Sessions is at the very forefront of the our conference mission to build healthier lives, free of cardiovascular disease and leads the world in innovative learning opportunities for attendees through unprecedented exposure to key thought leaders. This congress features many opportunities to network with colleagues from around the world in an exciting environment. The scope and quality of the scientific exchange make Scientific Sessions the premier cardiovascular research and instructional meeting in the world. This events features three days of the best in cardiovascular clinical practice and scientific content covering all aspects of basic, clinical, population and translational content.
If you require any further information please do not hesitate to contact the conference Manager at firstname.lastname@example.org
The risk for recurrent stroke associated with surgical aortic valve replacement (SAVR) is elevated if the procedure is done up to a year or longer after a prior stroke, but it is an order of magnitude higher in the first 3 months, a new report suggests.
The US Food and Drug Administration (FDA) has approved Medtronic's IN.PACT Admiral drug-coated balloon (DCB) to treat long superficial femoral artery (SFA) lesions up to 360 mm in patients with peripheral artery disease (PAD), the company announced.
People who are obese but without cardiometabolic risk factors, who have so-called metabolically healthy obesity (MHO), may appear to be at low risk for cardiovascular (CV) events. But many, perhaps most, aren't off the hook.
Evidence of a previous silent or unrecognized myocardial infarction (UMI) is concerningly common and independently associated with poor prognosis in patients presenting with a clinical MI, data from an observational study showed.
Two US Food and Drug Administration (FDA) panels today jointly voted by a large margin that the cardiovascular (CV) safety of celecoxib (Celebrex, Pfizer) is comparable to naproxen and ibuprofen.
Copyrights © 2016-17 Innovinc Pvt Ltd All Rights Reserved